Summit Therapeutics reported a net loss of $613.5 million for the nine months ended September 30, 2026, compared to a net loss of $860.4 million in the prior year period. The company ended the quarter with $629.8 million in cash, cash equivalents, and short-term investments, while total stockholders' equity decreased to $564.7 million from $658.9 million at year-end 2025.
Summit Therapeutics reported its Q3 2026 financial results, highlighting a $2.0 billion strategic equity investment from AstraZeneca received post-quarter. The company ended the period with $629.8 million in cash and is advancing its global clinical development program for ivonescimab across multiple solid tumor indications.
“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others.”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit
“Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC- 20 platform study.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit